ociperlimab + tislelizumab + chemotherapy

**Ociperlimab + tislelizumab + chemotherapy** is a combination regimen consisting of two investigational humanized monoclonal antibodies—**ociperlimab** (BGB-A1217), which targets TIGIT (T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains), and **tislelizumab** (BGB-A317), which targets PD-1 (programmed cell death protein 1), both designed to enhance antitumor immune responses. This regimen is used in clinical trials for advanced or metastatic solid tumors and select specific cancers, often in combination with standard chemotherapies. Ociperlimab functions by blocking TIGIT, thereby activating immune cells, while tislelizumab blocks PD-1, rejuvenating exhausted T cells. Chemotherapy is added to enhance cytoreduction and immunogenic cell death. Clinical trials are ongoing to assess efficacy and safety, particularly in non-small cell lung cancer (NSCLC), cervical cancer, and other solid tumors[1][3].